---
title: "Roth MKM Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX)"
description: "Roth MKM analyst Boobalan Pachaiyappan has maintained a Buy rating on LB Pharmaceuticals, Inc. (LBRX) with a price target of $31.00. The analyst focuses on the Healthcare sector and has an average ret"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273861458.md"
published_at: "2026-01-27T14:55:59.000Z"
---

# Roth MKM Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX)

> Roth MKM analyst Boobalan Pachaiyappan has maintained a Buy rating on LB Pharmaceuticals, Inc. (LBRX) with a price target of $31.00. The analyst focuses on the Healthcare sector and has an average return of 6.3% with a 45.30% success rate on recommendations. The consensus on LB Pharmaceuticals is a Strong Buy, with an average price target of $48.00.

Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on LB Pharmaceuticals, Inc. today and set a price target of $31.00.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Pachaiyappan covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, PolyPid, and CervoMed. According to TipRanks, Pachaiyappan has an average return of 6.3% and a 45.30% success rate on recommended stocks.

Currently, the analyst consensus on LB Pharmaceuticals, Inc. is a Strong Buy with an average price target of $48.00.

### Related Stocks

- [LBRX.US - LB Pharmaceuticals](https://longbridge.com/en/quote/LBRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| LB Pharmaceuticals, Inc. (LBRX) Receives a New Rating from Roth MKM | LB Pharmaceuticals, Inc. (LBRX) has received a Buy rating and a price target of $31.00 from Roth MKM analyst Boobalan Pa | [Link](https://longbridge.com/en/news/272027134.md) |
| Evercore ISI Sticks to Their Buy Rating for CVS Health (CVS) | Evercore ISI analyst Elizabeth Anderson maintained a Buy rating on CVS Health (CVS) with a price target of $100.00. Ande | [Link](https://longbridge.com/en/news/275622408.md) |
| Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) | Berenberg Bank analyst Kerry Holford has reaffirmed a Buy rating on Novo Nordisk (0QIU) with a price target of DKK360.00 | [Link](https://longbridge.com/en/news/275719942.md) |
| J.P. Morgan Reaffirms Their Buy Rating on Sartorius (0NIR) | J.P. Morgan analyst Richard Vosser has reaffirmed a Buy rating on Sartorius (0NIR) with a price target of €295.00. Vosse | [Link](https://longbridge.com/en/news/275586209.md) |
| What 5 Analyst Ratings Have To Say About Mohawk Industries | Mohawk Industries (NYSE:MHK) received mixed ratings from 5 analysts, with an average 12-month price target of $121.2, re | [Link](https://longbridge.com/en/news/275665682.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.